Pharmaceutical & Drug Policy
Comments on Medicare Drug Price Negotiation Program’s Section 30.2 and Part B high spend drugs
On January 31, the Engelberg Center for Health Care Reform hosted the live webinar, “Mini-Sentinel Accomplishments and Plans for Year Two,” as part of the Brookings Roundtable on Active Medical Product Surveillance series.
The webinar served as an opportunity for interested stakeholders to revisit discussions from the Sentinel Initiative Public Workshop, and focused on Mini-Sentinel’s progress and plans for the upcoming year.
Brookings Roundtable on Active Medical Product Surveillance: Mini-Sentinel Accomplishments and Plans for Year Two
Agenda
-
January 31
-
Welcome and Introductions
Mark B. McClellan Former Brookings Expert, Director, Margolis Center for Health Policy - Duke University -
Sentinel Today: FDA Perspective
JRJudy Racoosin Sentinel Initiative Scientific Lead, Office of Medical Policy, Center for Drug Evaluation and Research -
Status Report on Mini-Sentinel
RPRichard Platt Professor and Chair, Department of Population Medicine - Harvard Pilgrim Health Care Institute -
Development of a Common Data Model and Distributed Analysis
LHCLesley Huntley Curtis Associate Professor in Medicine - Duke University School of Medicine -
Privacy and Security in Mini-Sentinel
DMDeven McGraw Director, Health Privacy Project -
Plans for Surveillance of Users of Oral Ant-Diabetes Drugs
-
